← brief for 2026-08-13 · Slowing decline

XIGDUO XR

Drug label A Peer reviewed Meta-analysis or large trial

Key takeaways

This combination drug was studied to reduce kidney decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes. The study used a combination of two drugs: dapagliflozin and metformin extended-release.

Who did this work

AstraZeneca Pharmaceuticals LP

Source

Drug label · openFDA, renal drug labels · 2026-08-11
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac8a0f7b-9f69-4495-abbc-3a47cd75a859